Floatz logo

BARDOXOLONE METHYL ESTER

Autosomal Dominant Polycystic Kidney

BiogenSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Autosomal Dominant Polycystic Kidney cohort.

Asset / SponsorPhaseRating
Everolimus
Assistance Publique - Hôpitaux de Paris
Phase 3B
Tirzepatide
University of Colorado, Denver
Phase 2CCC

Same molecule, other indications

BARDOXOLONE METHYL ESTER is also rated in:

pulmonary hypertensionDormant
B
Indicative ·
57 / 100
View asset →
pulmonary arterial hypertensionDormant
B
Indicative ·
57 / 100
View asset →
interstitial lung diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →